Active Portfolio Companies
Autobahn is a biotechnology company developing a pipeline of transformative small molecule therapies for the treatment of CNS disorders. The company’s lead program leverages a brain-targeting chemistry platform to target the unambiguous link between thyroid hormone and myelin biology for AMN and MS.
BlueLight Therapeutics is a biotechnology company that uses a novel structure-function-based approach to develop new therapeutic molecules against challenging drug targets to treat a wide range of serious diseases.
Bolt is a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer. The company’s lead ISAC is delivered systemically as monotherapy for HER2-expressing cancers.
Complexa is a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases. The company is leveraging its differentiated endogenous nitrated fatty acid cell signaling technology platform, to focus on Focal Segmental Glomerulosclerosis (FSGS) and Pulmonary Arterial Hypertension (PAH). Complexa believes its approach has the ability to not only halt, but to reverse, disease related fibrosis. The company’s lead product CXA-10 is in Phase 2 trials.
eFFECTOR is a clinical stage biopharmaceutical company pioneering the discovery and development of selective translation regulators as a new class of small molecule drugs for treating cancer. The company’s investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTOR’s most advanced program focuses on the development of tomivosertib, which is in Phase 2 studies.
EvolveImmune is rapidly transforming the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets which are expressed on multiple immune cell types, with the aim to generate first-in-class treatments for unmet needs in oncology and autoimmune diseases.
TRex Bio is a stealth mode, discovery-stage biotechnology company focused on making a meaningful difference in the lives of patients suffering from fatal or debilitating illnesses including cancer, fibrotic, autoimmune and inflammatory diseases. TRex aims to achieve this vision via functional manipulation of Tregs and other immune cells in a tissue-specific and disease-specific fashion.
Former Portfolio Companies
Petra Pharma is a drug development company focused on novel enzyme targets that play a central role in a variety of important cellular processes, including cell division, growth, trafficking, and signaling. Petra Pharma will develop novel small molecules for the treatment of cancer and metabolic diseases to target these cellular processes in order to therapeutically impact human health.